Celltrion signed a three-year contract manufacturing agreement to supply drug substance from 2027 through 2029 with a contract value of approximately 294.9 billion KRW. The deal provides multi-year revenue visibility beginning in 2027 and is material to Celltrion's manufacturing business. This contract could modestly boost near-term earnings and is likely to move the company's stock on execution and revenue recognition.
Celltrion signed a three-year contract manufacturing agreement to supply drug substance from 2027 through 2029 with a contract value of approximately 294.9 billion KRW. The deal provides multi-year revenue visibility beginning in 2027 and is material to Celltrion's manufacturing business. This contract could modestly boost near-term earnings and is likely to move the company's stock on execution and revenue recognition.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
